Alnylam Pharmaceuticals (NASDAQ:ALNY) Sets New 12-Month High - Should You Buy?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $317.45 and last traded at $316.77, with a volume of 236069 shares traded. The stock had previously closed at $308.71.

Analysts Set New Price Targets

Several equities analysts have commented on the company. UBS Group increased their price target on Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Citigroup lifted their target price on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a "buy" rating in a report on Friday, March 21st. JPMorgan Chase & Co. upped their price target on shares of Alnylam Pharmaceuticals from $330.00 to $338.00 and gave the company an "overweight" rating in a report on Thursday, June 12th. Canaccord Genuity Group lifted their price objective on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a research note on Friday, March 21st. Finally, Royal Bank Of Canada increased their target price on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an "outperform" rating in a research note on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $319.58.

Alnylam Pharmaceuticals Trading Down 0.8%

The stock has a market cap of $40.38 billion, a P/E ratio of -148.18 and a beta of 0.22. The business's 50 day simple moving average is $277.63 and its 200 day simple moving average is $261.04. The company has a debt-to-equity ratio of 8.88, a current ratio of 3.04 and a quick ratio of 2.98.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The company had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. During the same quarter last year, the business earned ($0.16) EPS. Alnylam Pharmaceuticals's quarterly revenue was up 20.2% compared to the same quarter last year. On average, analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 19,297 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total value of $5,904,882.00. Following the transaction, the chief executive officer now directly owns 48,948 shares of the company's stock, valued at $14,978,088. The trade was a 28.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.50% of the company's stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. SVB Wealth LLC bought a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth $27,000. Whipplewood Advisors LLC grew its holdings in Alnylam Pharmaceuticals by 208.8% during the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 71 shares during the last quarter. Bessemer Group Inc. increased its position in Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 69 shares in the last quarter. Larson Financial Group LLC increased its position in Alnylam Pharmaceuticals by 187.2% in the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 73 shares in the last quarter. Finally, Park Square Financial Group LLC bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $28,000. Institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.